APR 24, 2014 08:00 AM PDT
Heparin-Induced Thrombocytopenia (HIT): Pathophysiology, Diagnosis, Clinical Presentation and Management
Presented at the Stago EdVantage Virtual University Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
1 3 189

Speakers:
  • Prof. of Pathology, Medicine & Pediatrics Director of Hemostasis & Thrombosis, Oregon Health & Science University (OHSU)
    Biography
      Dr. Boshkov specializes in coagulation abnormalities and testing, and blood transfusion, including support of Jehovah's Witness patients. She is the principal investigator in clinical trials to determine if the use of prestorage leukoreduced blood products modifies the outcome in cardiac surgery patients. Dr. Boshkov heads hemostasis and thrombosis at OHSU, and is the associate director of transfusion medicine. She is married with two sons, and is fluent in French.

    Abstract:
    Heparin-induced thrombocytopenia (HIT) is a potentially serious complication associated with unfractionated heparin (UFH) and low molecular weight heparin (LMWH) therapy.  Patients suspected of HIT must be moved to alternative anticoagulants which are much more expensive compared to UFH and LMWH, making timely and accurate screening and confirmation of HIT critical to minimize the costs associated with patient care.  Diagnosis of HIT is performed both by use of a clinical probability scoring method and clinical laboratory diagnostics which involve both screening and confirmatory assays.  The presentation will provide attendees with an overview of HIT along with clinical scoring, laboratory diagnostic methods, and available alternative treatments. 
    • Describe the clinical presentation of HIT.
    • Relate the pathophysiology of HIT.
    • Identify and discuss the diagnostic tests for HIT.
    • Provide therapeutic options for treating HIT.

    Show Resources
    Loading Comments...